Abstract
Ropivacaine is a new amide local anaesthetic, which is the first commercially available in its category as a pure S-(-) enantiomer. In most recent studies [40], ropivacaine exhibited a very close pharmacodynamic profile to equipotent doses of bupivacaine. Concentrations of 0.5percent, 0.75percent and 1percent (5, 7.5 and 10 mg / mL, respectively) ropivacaine are used for intraoperative anaesthesia, while the concentration of 0.2percent (2 mg / mL) is preferred for postoperative analgesia, either alone or in combination with opioids and / or clonidine. Ropivacaine is responsible for excellent postoperative analgesia following epidural and peripheral perineural injections, using single-shot injections and continuous infusions. Differential sensory / motor block is only apparent at low concentrations (0.2percent and less). A significant amount of recent literature focuses on its use for peripheral blocks of the lower limbs, i.e. sciatic and femoral nerve blocks. The primary benefit of ropivacaine is its lower toxicity, mainly lower cardiotoxicity, following accidental intravascular injection. This higher therapeutic index leads to an improved safety profile as compared with potent local anaesthetics such as racemic bupivacaine. For that reason, ropivacaine is a good choice for both intraoperative and postoperative regional anaesthesia and analgesia.
Keywords: Ropivacaine, local anaesthetic, Epidural Administration, LOWER LIMB SURGERY, Sciatic Nerve Blocks, Postoperative Analgesia
Current Topics in Medicinal Chemistry
Title: Clinical Application of Ropivacaine for the Lower Extremity
Volume: 1 Issue: 3
Author(s): Jean-Jacques Eledjam, Jacques Ripart and Eric Viel
Affiliation:
Keywords: Ropivacaine, local anaesthetic, Epidural Administration, LOWER LIMB SURGERY, Sciatic Nerve Blocks, Postoperative Analgesia
Abstract: Ropivacaine is a new amide local anaesthetic, which is the first commercially available in its category as a pure S-(-) enantiomer. In most recent studies [40], ropivacaine exhibited a very close pharmacodynamic profile to equipotent doses of bupivacaine. Concentrations of 0.5percent, 0.75percent and 1percent (5, 7.5 and 10 mg / mL, respectively) ropivacaine are used for intraoperative anaesthesia, while the concentration of 0.2percent (2 mg / mL) is preferred for postoperative analgesia, either alone or in combination with opioids and / or clonidine. Ropivacaine is responsible for excellent postoperative analgesia following epidural and peripheral perineural injections, using single-shot injections and continuous infusions. Differential sensory / motor block is only apparent at low concentrations (0.2percent and less). A significant amount of recent literature focuses on its use for peripheral blocks of the lower limbs, i.e. sciatic and femoral nerve blocks. The primary benefit of ropivacaine is its lower toxicity, mainly lower cardiotoxicity, following accidental intravascular injection. This higher therapeutic index leads to an improved safety profile as compared with potent local anaesthetics such as racemic bupivacaine. For that reason, ropivacaine is a good choice for both intraoperative and postoperative regional anaesthesia and analgesia.
Export Options
About this article
Cite this article as:
Eledjam Jean-Jacques, Ripart Jacques and Viel Eric, Clinical Application of Ropivacaine for the Lower Extremity, Current Topics in Medicinal Chemistry 2001; 1 (3) . https://dx.doi.org/10.2174/1568026013395317
DOI https://dx.doi.org/10.2174/1568026013395317 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neural Stem Cell Plasticity: Recruitment of Endogenous Populations for Regeneration
Current Neurovascular Research Opportunities and Challenges for Host-Directed Therapies in Tuberculosis
Current Pharmaceutical Design Antifungal Agents in Hematopoietic Stem Cell Transplantation
Current Pharmaceutical Design Allopurinol Hypersensitivity Reactions: Desensitization Strategies and New Therapeutic Alternative Molecules
Inflammation & Allergy - Drug Targets (Discontinued) Pharmacological Targets for the Inhibition of Neurogenic Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Pathogenesis and Immune Status in COVID-19 Pneumonia - A Minireview
Coronaviruses NK-1 Receptor Antagonists: A New Generation of Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology Temporal Progression of Kainic Acid Induced Changes in Vascular Laminin Expression in Rat Brain with Neuronal and Glial Correlates
Current Neurovascular Research Stem Cell and Gene Therapeutic Strategies for the Treatment of Multiple Sclerosis
Current Molecular Medicine Methods to Measure Target Site Penetration of Antibiotics in Critically Ill Patients
Current Clinical Pharmacology Proteome Analysis of Formalin-Fixed Paraffin-Embedded Tissues from a Primary Gastric Melanoma and its Meningeal Metastasis: A Case Report
Current Topics in Medicinal Chemistry Replicative Oncolytic Herpes Simplex Viruses in Combination Cancer Therapies
Current Gene Therapy Chronic Cerebral Hypoperfusion Protects Against Acute Focal Ischemia,Improves Motor Function, and Results in Vascular Remodeling
Current Neurovascular Research A New Frontier in the Treatment of Cancer: NK-1 Receptor Antagonists
Current Medicinal Chemistry Rediscovering the Antibiotics of the Hive
Recent Patents on Anti-Infective Drug Discovery Advances in Metabonomics on Infectious Diseases
Current Metabolomics TB Diagnostics – Old and New
Current Respiratory Medicine Reviews Role of Grina/Nmdara1 in the Central Nervous System Diseases
Current Neuropharmacology Preliminary Anti-Coxsackie Activity of Novel 1-[4-(5,6-dimethyl(H)- 1H(2H)-benzotriazol-1(2)-yl)phenyl]-3-alkyl(aryl)ureas
Medicinal Chemistry